Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL

Journal of Lipid Research

Volumn 54, Issue 2, 2013, Pages 552-560

  Kim, Daniel S ^a   Burt, Amber A ^a   Crosslin, David R ^a   Robertson, Peggy D ^a   Ranchalis, Jane E ^a   Boyko, Edward J ^b   Nickerson, Deborah A ^a   Furlong, Clement E ^a   Jarvik, Gail P ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Atherosclerosis; Diabetes; Exome chip

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; VASPIN;

AGED; ARTICLE; ARYLDIALKYLPHOSPHATASE 1 GENE; CARDIOVASCULAR DISEASE; EXOME; FEMALE; FTO GENE; GENE ACTIVITY; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; ITGAL GENE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VASPIN GENE;

AGED; ANTIGENS, CD11A; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; CONSERVED SEQUENCE; EVOLUTION, MOLECULAR; EXOME; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MULTIGENE FAMILY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; SERPINS;

EID: 84872458017     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P033266     Document Type: Article

References (75)

1. Mackness, M. I., S. Arrol, C. Abbott, and P. N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104: 129-135. (Pubitemid 24035640)
2. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
3. Besler, C., K. Heinrich, L. Rohrer, C. Doerries, M. Riwanto, D. M. Shih, A. Chroni, K. Yonekawa, S. Stein, N. Schaefer, et al. 2011. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest. 121: 2693-2708.
4. Shih, D. M., L. Gu, Y. R. Xia, M. Navab, W. F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, et al. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287. (Pubitemid 28335041)
5. Shih, D. M., Y. R. Xia, X. P. Wang, E. Miller, L. W. Castellani, G. Subbanagounder, H. Cheroutre, K. F. Faull, J. A. Berliner, J. L. Witztum, et al. 2000. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275: 17527-17535. (Pubitemid 30430794)
6. Boden, W. E., J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365: 2255-2267.
7. Haase, C. L., A. Tybjaerg-Hansen, A. A. Qayyum, J. Schou, B. G. Nordestgaard, and R. Frikke-Schmidt. 2012. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J. Clin. Endocrinol. Metab. 97: E248-E256.
8. Voight, B. F., G. M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M. K. Jensen, G. Hindy, H. Holm, E. L. Ding, T. Johnson, et al. 2012. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 380: 572-580.
9. Costa, L. G., B. E. McDonald, S. D. Murphy, G. S. Omenn, R. J. Richter, A. G. Motulsky, and C. E. Furlong. 1990. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol. Appl. Pharmacol. 103: 66-76. (Pubitemid 20115985)
10. Richter, R. J., G. P. Jarvik, and C. E. Furlong. 2008. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ. Cardiovasc. Genet. 1: 147-152.
11. Richter, R. J., G. P. Jarvik, and C. E. Furlong. 2009. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol. Appl. Pharmacol. 235: 1-9.
12. Furlong, C. E., N. Holland, R. J. Richter, A. Bradman, A. Ho, and B. Eskenazi. 2006. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet. Genomics. 16: 183-190.
13. Richter, R. J., G. P. Jarvik, and C. E. Furlong. 2010. Paraoxonase 1 status as a risk factor for disease or exposure. In Paraoxonases in Inflammation, Infection, and Toxicology. S. T. Reddy, editor. Humana Press. 29-35.
14. Brophy, V. H., M. Hastings, J. B. Clendenning, R. J. Richter, G. P. Jarvik, and C. E. Furlong. 2001. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics. 11: 77-84. (Pubitemid 32108664)
15. Leviev, I., and R. W. James. 2000. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20: 516-521. (Pubitemid 30086111)
16. Kim, D. S., A. A. Burt, J. E. Ranchalis, R. J. Richter, J. Marshall, J. F. Eintracht, E. A. Rosenthal, C. E. Furlong, and G. P. Jarvik. 2012. Additional common polymorphisms in the PON gene cluster predict PON1 activity but not vascular disease. J. Lipids. 2012: 476316.
17. Jarvik, G. P., R. Jampsa, R. J. Richter, C. Carlson, M. Rieder, D. Nickerson, and C. E. Furlong. 2003. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics. 13: 291-295. (Pubitemid 36583997)
18. Kim, D. S., A. A. Burt, J. E. Ranchalis, R. J. Richter, J. K. Marshall, K. S. Nakayama, E. R. Jarvik, J. F. Eintracht, E. A. Rosenthal, C. E. Furlong, et al. 2012. Dietary cholesterol increases paraoxonase 1 enzyme activity. J. Lipid Res. 53: 2450-2458.
19. Eichler, E. E., J. Flint, G. Gibson, A. Kong, S. M. Leal, J. H. Moore, and J. H. Nadeau. 2010. Missing heritability and strategies for finding the underlying causes of complex disease. Nat. Rev. Genet. 11: 446-450.
20. Manolio, T. A., F. S. Collins, N. J. Cox, D. B. Goldstein, L. A. Hindorff, D. J. Hunter, M. I. McCarthy, E. M. Ramos, L. R. Cardon, A. Chakravarti, et al. 2009. Finding the missing heritability of complex diseases. Nature. 461: 747-753.
21. Maher, B. 2008. Personal genomes: the case of the missing heritability. Nature. 456: 18-21.
22. McClellan, J., and M. C. King. 2010. Genetic heterogeneity in human disease. Cell. 141: 210-217.
23. Jarvik, G. P., T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al. 2003. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 23: 1465-1471. (Pubitemid 36994538)
24. Jarvik, G. P., L. S. Rozek, V. H. Brophy, T. S. Hatsukami, R. J. Richter, G. D. Schellenberg, and C. E. Furlong. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler. Thromb. Vasc. Biol. 20: 2441-2447.
25. Ronald, J., R. Rajagopalan, J. Ranchalis, J. Marshall, T. Hatsukami, P. Heagerty, and G. Jarvik. 2009. Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease. Lipids Health Dis. 8: 52.
26. Pritchard, J. K., M. Stephens, and P. Donnelly. 2000. Inference of population structure using multilocus genotype data. Genetics. 155: 945-959. (Pubitemid 30397141)
27. Brophy, V. H., R. L. Jampsa, J. B. Clendenning, L. A. McKinstry, G. P. Jarvik, and C. E. Furlong. 2001. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet. 68: 1428-1436. (Pubitemid 32510618)
28. Illumina. 2010. HumanCVD Genotyping BeadChip. (Data sheet). Illumina, San Diego.
29. Illumina. 2012. HumanExome BeadChips. (Data sheet). Illumina, San Diego.
30. Purcell, S., B. Neale, K. Todd-Brown, L. Thomas, M. A. R. Ferreira, D. Bender, J. Maller, P. Sklar, P. I. W. de Bakker, M. J. Daly, et al. 2007. PLINK: a tool set for whole-genome association and population- based linkage analyses. Am. J. Hum. Genet. 81: 559-575. (Pubitemid 47330214)
31. Wu, M. C., S. Lee, T. Cai, Y. Li, M. Boehnke, and X. Lin. 2011. Rarevariant association testing for sequencing data with the sequence kernel association test. Am. J. Hum. Genet. 89: 82-93.
32. Siepel, A., G. Bejerano, J. S. Pedersen, A. S. Hinrichs, M. Hou, K. Rosenbloom, H. Clawson, J. Spieth, L. W. Hillier, S. Richards, et al. 2005. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 15: 1034-1050. (Pubitemid 41126859)
33. Cooper, G. M., D. L. Goode, S. B. Ng, A. Sidow, M. J. Bamshad, J. Shendure, and D. A. Nickerson. 2010. Single-nucleotide evolutionary constraint scores highlight disease-causing mutations. Nat. Methods. 7: 250-251.
34. Riedmaier, S., K. Klein, S. Winter, U. Hofmann, M. Schwab, and U. Zanger. 2011. Paraoxonase (PON1 and PON3) polymorphisms: impact on liver expression and atorvastatin-lactone hydrolysis. Front Pharmacol. 2: 41.
35. Ozer, E. A., A. Pezzulo, D. M. Shih, C. Chun, C. E. Furlong, A. J. Lusis, E. P. Greenberg, and J. Zabner. 2005. Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. FEMS Microbiol. Lett. 253: 29-37. (Pubitemid 41605391)
36. Stoltz, D. A., E. A. Ozer, P. J. Taft, M. Barry, L. Liu, P. J. Kiss, T. O. Moninger, M. R. Parsek, and J. Zabner. 2008. Drosophila are protected from Pseudomonas aeruginosa lethality by transgenic expression of paraoxonase-1. J. Clin. Invest. 118: 3123-3131.
37. Akhmedova, S. N., A. K. Yakimovsky, and E. I. Schwartz. 2001. Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J. Neurol. Sci. 184: 179-182. (Pubitemid 32178272)
38. Carmine, A., S. Buervenich, O. Sydow, M. Anvret, and L. Olson. 2002. Further evidence for an association of the Paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Mov. Disord. 17: 764-766. (Pubitemid 41295021)
39. Kelada, S. N., P. Costa-Mallen, H. Checkoway, H. A. Viernes, F. M. Farin, T. Smith-Weller, G. M. Franklin, L. G. Costa, W. T. Longstreth, C. E. Furlong, et al. 2003. Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 74: 546-547. (Pubitemid 36379392)
40. Kondo, I., and M. Yamamoto. 1998. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res. 806: 271-273. (Pubitemid 29010502)
41. Zintzaras, E., and G. M. Hadjigeorgiou. 2004. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. J. Hum. Genet. 49: 474-481. (Pubitemid 39314366)
42. Dasgupta, S., F. Y. Demirci, A. Dressen, A. Kao, E. Rhew, R. Ramsey- Goldman, S. Manzi, C. Kammerer, and M. I. Kamboh. 2011. Association analysis of PON2 genetic variants with serum paraoxonase activity and systemic lupus erythematosus. BMC Med. Genet. 12: 7.
43. Kiss, E., I. Seres, T. Tarr, Z. Kocsis, G. Szegedi, and G. Paragh. 2007. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1108: 83-91. (Pubitemid 47528720)
44. Tripi, L. M., S. Manzi, Q. Chen, M. Kenney, P. Shaw, A. Kao, F. Bontempo, C. Kammerer, and M. I. Kamboh. 2006. Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum. 54: 1928-1939. (Pubitemid 43877942)
45. Liu, C., and L. Liu. 2011. Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis. Tumour Biol. 32: 1233-1240.
46. Saadat, M. 2011. Paraoxonase 1 genetic polymorphisms and susceptibility to breast cancer: a meta-analysis. Cancer Epidemiol. 36: e101-e103.
47. Pauer, G. J. T., G. M. Sturgill, N. S. Peachey, and S. A. Hagstrom. 2010. Protective effect of paraoxonase 1 gene variant Gln192Arg in age-related macular degeneration. Am. J. Ophthalmol. 149: 513-522.
48. Baird, P. N., D. Chu, E. Guida, H. T. V. Vu, and R. Guymer. 2004. Association of the M55L and Q192R paraoxonase gene polymorphisms with age-related macular degeneration. Am. J. Ophthalmol. 138: 665-666. (Pubitemid 39420506)
49. Baskol, G., S. Karakucuk, A. Oner, M. Baskol, D. Kocer, E. Mirza, R. Saraymen, and M. Ustdal. 2006. Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica. 220: 12-16. (Pubitemid 41832689)
50. Mackness, B., M. I. Mackness, S. Arrol, W. Turkie, K. Julier, B. Abuasha, J. E. Miller, A. J. M. Boulton, and P. N. Durrington. 1998. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 139: 341-349. (Pubitemid 28361819)
51. Furlong, C. E., S. M. Suzuki, R. C. Stevens, J. Marsillach, R. J. Richter, G. P. Jarvik, H. Checkoway, A. Samii, L. G. Costa, A. Griffith, et al. 2010. Human PON1, a biomarker of risk of disease and exposure. Chem. Biol. Interact. 187: 355-361.
52. Scott, L. J., K. L. Mohlke, L. L. Bonnycastle, C. J. Willer, Y. Li, W. L. Duren, M. R. Erdos, H. M. Stringham, P. S. Chines, A. U. Jackson, et al. 2007. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 316: 1341-1345. (Pubitemid 46871655)
53. Zeggini, E., M. N. Weedon, C. M. Lindgren, T. M. Frayling, K. S. Elliott, H. Lango, N. J. Timpson, J. R. Perry, N. W. Rayner, R. M. Freathy, et al. 2007. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 316: 1336-1341. (Pubitemid 46871654)
54. Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 447: 661-678.
55. Frayling, T. M., N. J. Timpson, M. N. Weedon, E. Zeggini, R. M. Freathy, C. M. Lindgren, J. R. Perry, K. S. Elliott, H. Lango, N. W. Rayner, et al. 2007. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 316: 889-894. (Pubitemid 46764279)
56. Dina, C., D. Meyre, S. Gallina, E. Durand, A. Korner, P. Jacobson, L. M. Carlsson, W. Kiess, V. Vatin, C. Lecoeur, et al. 2007. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat. Genet. 39: 724-726. (Pubitemid 46848595)
57. Malzahn, D., Y. Balavarca, J. P. Lozano, and H. Bickeboller. 2009. Tests for candidate-gene interaction for longitudinal quantitative traits measured in a large cohort. BMC Proc. 3 (Suppl. 7) : S80.
58. Hida, K., J. Wada, J. Eguchi, H. Zhang, M. Baba, A. Seida, I. Hashimoto, T. Okada, A. Yasuhara, A. Nakatsuka, et al. 2005. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc. Natl. Acad. Sci. USA. 102: 10610-10615. (Pubitemid 41061602)
59. Youn, B. S., N. Kloting, J. Kratzsch, N. Lee, J. W. Park, E. S. Song, K. Ruschke, A. Oberbach, M. Fasshauer, M. Stumvoll, et al. 2008. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 57: 372-377.
60. Kempf, K., B. Rose, T. Illig, W. Rathmann, K. Strassburger, B. Thorand, C. Meisinger, H. E. Wichmann, C. Herder, and C. Vollmert. 2010. Vaspin (SERPINA12) genotypes and risk of type 2 diabetes: results from the MONICA/KORA studies. Exp. Clin. Endocrinol. Diabetes. 118: 184-189.
61. Klöting, N., J. Berndt, S. Kralisch, P. Kovacs, M. Fasshauer, M. R. Schon, M. Stumvoll, and M. Bluher. 2006. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem. Biophys. Res. Commun. 339: 430-436. (Pubitemid 41697566)
62. Koren-Gluzer, M., M. Aviram, E. Meilin, and T. Hayek. 2011. The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates B-cell insulin release. Atherosclerosis. 219: 510-518.
63. Saxena, R., C. C. Elbers, Y. Guo, I. Peter, T. R. Gaunt, J. L. Mega, M. B. Lanktree, A. Tare, B. A. Castillo, Y. R. Li, et al. 2012. Largescale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am. J. Hum. Genet. 90: 410-425.
64. Fawcett, J., C. L. Holness, L. A. Needham, H. Turley, K. C. Gatter, D. Y. Mason, and D. L. Simmons. 1992. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature. 360: 481-484.
65. Wu, D., Z. Ren, M. Pae, W. Guo, X. Cui, A. H. Merrill, and S. N. Meydani. 2007. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J. Immunol. 179: 4829-4839.
66. Nofer, J. R. 2012. Hyperlipidaemia and cardiovascular disease: HDL, inflammation and surprising results of AIM-HIGH study. Curr. Opin. Lipidol. 23: 260-262.
67. Carty, C. L., P. Heagerty, K. Nakayama, E. C. McClung, J. Lewis, D. Lum, E. Boespflug, C. McCloud-Gehring, B. R. Soleimani, J. Ranchalis, et al. 2006. Inflammatory response after influenza vaccination in men with and without carotid artery disease. Arterioscler. Thromb. Vasc. Biol. 26: 2738-2744.
68. Van Lenten, B. J., A. C. Wagner, D. P. Nayak, S. Hama, M. Navab, and A. M. Fogelman. 2001. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation. 103: 2283-2288. (Pubitemid 32433719)
69. Marsillach, J., J. Camps, N. Ferre, R. Beltran, A. Rull, B. Mackness, M. Mackness, and J. Joven. 2009. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterol. 9: 3.
70. Cyrus, T., D. Pratico, L. Zhao, J. L. Witztum, D. J. Rader, J. Rokach, G. A. FitzGerald, and C. D. Funk. 2001. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation. 103: 2277-2282. (Pubitemid 32433718)
71. George, J., A. Afek, A. Shaish, H. Levkovitz, N. Bloom, T. Cyrus, L. Zhao, C. D. Funk, E. Sigal, and D. Harats. 2001. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptordefi cient mice. Circulation. 104: 1646-1650. (Pubitemid 32947528)
72. Burdon, K. P., M. E. Rudock, A. B. Lehtinen, C. D. Langefeld, D. W. Bowden, T. C. Register, Y. Liu, B. I. Freedman, J. J. Carr, C. C. Hedrick, et al. 2010. Human lipoxygenase pathway gene variation and association with markers of subclinical atherosclerosis in the diabetes heart study. Mediators Inflamm. 2010: 170153.
73. Liu, Y., B. I. Freedman, K. P. Burdon, C. D. Langefeld, T. Howard, D. Herrington, D. C. Goff, Jr., D. W. Bowden, L. E. Wagenknecht, C. C. Hedrick, et al. 2008. Association of arachidonate 12-lipoxygenase genotype variation and glycemic control with albuminuria in type 2 diabetes. Am. J. Kidney Dis. 52: 242-250. (Pubitemid 351978132)
74. Reddy, S. T., D. J. Wadleigh, V. Grijalva, C. Ng, S. Hama, A. Gangopadhyay, D. M. Shih, A. J. Lusis, M. Navab, and A. M. Fogelman. 2001. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 21: 542-547. (Pubitemid 32323386)
75. Ng, C. J., D. J. Wadleigh, A. Gangopadhyay, S. Hama, V. R. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy. 2001. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276: 44444-44449.